Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

被引：14
|
作者：
Tone, Mari [1 ]
Izumo, Takehiro [1 ]
Awano, Nobuyasu [1 ]
Kuse, Naoyuki [1 ]
Inomata, Minoru [1 ]
Jo, Tatsunori [1 ]
Yoshimura, Hanako [1 ]
Miyamoto, Shingo [2 ]
Kunitoh, Hideo [2 ]
机构：
[1] Japanese Red Cross Med Ctr, Dept Resp Med, Shibuya Ku, Tokyo, Japan
[2] Japanese Red Cross Med Ctr, Dept Med Oncol, Shibuya Ku, Tokyo, Japan
来源：
LUNG CANCER MANAGEMENT | 2019年 / 8卷 / 02期
关键词：
immune checkpoint inhibitor; NSCLC; salvage chemotherapy; RANDOMIZED PHASE-III; RESPONSE RATES; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; VINORELBINE; CARBOPLATIN; TRIAL; CELLS;
D O I：
10.2217/lmt-2019-0001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Integration of immune checkpoint inhibitors in the treatment of early stage lung cancer
    Schuler, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 13 - 13
  • [22] Immune checkpoint inhibitors for cancer treatment
    Junsik Park
    Minsuk Kwon
    Eui-Cheol Shin
    Archives of Pharmacal Research, 2016, 39 : 1577 - 1587
  • [23] Lung cancer, elderly and immune checkpoint inhibitors
    Casaluce, Francesca
    Sgambato, Assunta
    Maione, Paolo
    Spagnuolo, Alessia
    Gridelli, Cesare
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1474 - S1481
  • [24] Using Immune Checkpoint Inhibitors in Lung Cancer
    Marrone, Kristen A.
    Brahmer, Julie R.
    ONCOLOGY-NEW YORK, 2016, 30 (08): : 713 - 721
  • [25] Immune Checkpoint Inhibitors in Lung Cancer and Melanoma
    Madden, Kathleen
    Kasler, Mary Kate
    SEMINARS IN ONCOLOGY NURSING, 2019, 35 (05)
  • [26] Update on Immune Checkpoint Inhibitors in Lung Cancer
    Creelan, Benjamin C.
    CANCER CONTROL, 2014, 21 (01) : 80 - 89
  • [27] Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta-analysis of randomized controlled trials
    Longo, Vito
    Rizzo, Alessandro
    Catino, Annamaria
    Montrone, Michele
    Galetta, Domenico
    THORACIC CANCER, 2023, 14 (11) : 1029 - 1035
  • [28] Immune checkpoint inhibitors in lung cancer: an update
    Sullivan, Kevin
    Preeshagul, Isabel
    Budman, Daniel
    Seetharamu, Nagashree
    FUTURE ONCOLOGY, 2017, 13 (11) : 955 - 959
  • [29] Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients
    Ma, Junxun
    Sun, Danyang
    Wang, Jinliang
    Han, Chun
    Qian, Yuanyu
    Chen, Guangying
    Li, Xiaoyan
    Zhang, Juan
    Cui, Pengfei
    Du, Wushuang
    Wu, Zhaozhen
    Chen, Shixue
    Zheng, Xuan
    Yue, Zhichao
    Song, Jia
    Gao, Chan
    Cai, Shangli
    Hu, Yi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (03) : 365 - 372
  • [30] Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients
    Junxun Ma
    Danyang Sun
    Jinliang Wang
    Chun Han
    Yuanyu Qian
    Guangying Chen
    Xiaoyan Li
    Juan Zhang
    Pengfei Cui
    Wushuang Du
    Zhaozhen Wu
    Shixue Chen
    Xuan Zheng
    Zhichao Yue
    Jia Song
    Chan Gao
    Shangli Cai
    Yi Hu
    Cancer Immunology, Immunotherapy, 2020, 69 : 365 - 372
12345